| Trial ID: | L0704 |
| Source ID: | NCT02808351
|
| Associated Drug: |
Berberine
|
| Title: |
Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus|Chronic Kidney Disease
|
| Interventions: |
DRUG: Berberine
|
| Outcome Measures: |
Primary: Contrast-induced nephropathy, An absolute increase in serum creatinine (SCr) \>=0.5mg/dL（\>=44.2μmmol/L）or a \>= 25% increase in SCr from baseline to 72 hours after the procedure, 72 hours | Secondary: Major adverse renal events, The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes., 30 days
|
| Sponsor/Collaborators: |
Sponsor: Nanjing First Hospital, Nanjing Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
800
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-07
|
| Completion Date: |
2021-12
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-29
|
| Locations: |
Nanjing First Hospital, Nanjing, Jiangsu, 210006, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02808351
|
